Home › Research › Biomarkers
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease
Fleisher AS, Munsie LM, Perahia DGS, Andersen SW, Higgins IA, Hauck PM, Lo AC, Sims JR et al.. Neurology, 2024-02-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results A total of 360 participants (mean age = 75.4 years; female = 52.8%) were randomized, and 218 completed the treatment period. No treatment effect was demonstrated by flortaucipir PET, volumetric MRI, or neurofilament light chain (NfL) analyses. A dose-related increase in plasma phosphorylated tau181 and total tau was demonstrated. Zagotenemab treatment groups reported a higher incidence of adverse events (AEs) (85.1%) compared with the placebo group (74.6%). Discussion In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression compared with placebo.
What this study adds
Evidence grade: High
This is a trial of 360 participants. In a phase 2 trial of 360 people with early symptomatic Alzheimer's disease, the drug zagotenemab did not slow clinical disease progression compared with placebo, and imaging and blood markers showed no treatment effect. Reported effect size: 52.8%; 85.1%; 74.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fleisher, A. S., Munsie, L. M., Perahia, D. G. S., Andersen, S. W., Higgins, I. A., Hauck, P. M., et al. (2024). Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. Neurology. https://doi.org/10.1212/wnl.0000000000208061
Vancouver
Fleisher AS, Munsie LM, Perahia DGS, Andersen SW, Higgins IA, Hauck PM, et al. Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. Neurology. 2024. doi:10.1212/wnl.0000000000208061. PMID: 38386949.
BibTeX
@article{fleisher2024-38386949,
author = {Fleisher, A. S. and Munsie, L. M. and Perahia, D. G. S. and Andersen, S. W. and Higgins, I. A. and Hauck, P. M. and Lo, A. C. and Sims, JR. and others},
title = {{Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease}},
journal = {Neurology},
year = {2024},
doi = {10.1212/wnl.0000000000208061},
pmid = {38386949},
url = {https://doi.org/10.1212/wnl.0000000000208061}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results A total of 360 participants (mean age = 75.4 years; female = 52.8%) were randomized, and 218 completed the treatment period.
- No treatment effect was demonstrated by flortaucipir PET, volumetric MRI, or neurofilament light chain (NfL) analyses.
- A dose-related increase in plasma phosphorylated tau181 and total tau was demonstrated.
- Zagotenemab treatment groups reported a higher incidence of adverse events (AEs) (85.1%) compared with the placebo group (74.6%).
- Discussion In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression compared with placebo.
Why it matters
In a phase 2 trial of 360 people with early symptomatic Alzheimer's disease, the drug zagotenemab did not slow clinical disease progression compared with placebo, and imaging and blood markers showed no treatment effect. People taking zagotenemab also had more adverse events than those on placebo.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designclinical trial
- Participants360
- Effect size52.8%; 85.1%; 74.6%
- Evidence strengthHigh
How this study scored 72/100
Published in a leading specialty journal, and it is a randomized controlled trial. We have no data on senior author's track record, so that was left out: it earned 69 of the 96 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 360 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 4 / 7 | Cited 46 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 11.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 11.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 46 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Eli Lilly (United States): institution h-index 744 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38386949) |
| Free to read | 2 / 2 | Free to read |
| Points | 69 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 69 of the 96 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000208061
- PubMed: 38386949
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Related studies in Biomarkers from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.